Treating Idiopathic Inflammatory Myopathies Related Reduced Bone Mineral Density With Denosumab or Zoledronic Acid
Idiopathic Inflammatory Myopathies, Osteoporosis, Osteopenia
About this trial
This is an interventional treatment trial for Idiopathic Inflammatory Myopathies focused on measuring denosumab, zoledronic acid
Eligibility Criteria
All idiopathic inflammatory myopathies (IIMs) patients under follow-up in Kwong Wah Hospital are invited to participate in this study.
IIMs are diagnosed by rheumatologist according to Bohan and Peter Criteria. Eligible patients will have dual-energy X-ray absorptiometry (DEXA) scan performed at baseline.
Inclusion Criteria:
- Adult patients of at least 18 years of age and
- Evidence of reduced BMD in osteopenia (defined by T-score of -0.1 to -2.5) or osteoporosis range (defined by T-score of < -2.5) at baseline by dual-energy X-ray absorptiometry (DEXA) scan.
Exclusion Criteria:
- Pregnant patients
- Patients with juvenile onset of disease (<18 years of age)
- Patients with pre-existing metabolic bone conditions
- Patients who are already on osteoporotic treatment other than calcium and vitamin D (including bisphosphonates, denosumab, teriparatide, raloxifene or strontium)
- Patients who are contraindicated to denosumab or zoledronic acid including severe renal impairment and hypersensitivity
- Patients who are not able to give informed consent
Sites / Locations
- Kwong Wah Hospital
Arms of the Study
Arm 1
Arm 2
Experimental
Active Comparator
Denosumab group
Zoledronic acid
Patients randomized into the denosumab group will receive denosumab 60mg subcutaneously every 6 months, for a total duration of 1 year. DEXA scan would be repeated at 1 year.
Patients randomized into the denosumab group will receive one dose of zoledronic acid at 5mg intravenously. DEXA scan would be repeated at 1 year.